Molecular Phenotypes for Cystic Fibrosis Lung Disease
NCT01116414 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152
Last updated 2023-10-27
Summary
The purpose of this study is to develop an integrated view of molecular mechanisms underlying CF lung disease severity.
Conditions
- Cystic Fibrosis
- Lung Diseases
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
University of North Carolina, Chapel Hill
lead OTHER
Principal Investigators
-
Michael Knowles, MD · University of North Carollina at Chapel Hill
Eligibility
- Min Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-07-31
- Primary Completion
- 2011-12-13
- Completion
- 2023-10-25
Countries
- United States
Study Locations
More Related Trials
-
Early Intervention in Cystic Fibrosis Exacerbation
NCT01104402 ·Status: COMPLETED ·Phase: NA
-
Genetic Modifiers of Cystic Fibrosis Related Diabetes
NCT01113216 ·Status: ENROLLING_BY_INVITATION
-
Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
NCT02767297 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
NCT01805713 ·Status: COMPLETED
-
Costimulatory Molecules as Biomarkers in Cystic Fibrosis
NCT01353950 ·Status: COMPLETED
-
A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
NCT03093714 ·Status: COMPLETED ·Phase: PHASE1
-
Home Monitoring to Predict Exacerbation in Cystic Fibrosis
NCT02416375 ·Status: COMPLETED
-
Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies
NCT00727285 ·Status: COMPLETED
-
Development a Core Set for Adults With Cystic Fibrosis Based on the ICF
NCT06128499 ·Status: COMPLETED
-
Pulmonary Vascular Disease in CF
NCT04549077 ·Status: ACTIVE_NOT_RECRUITING
-
Nutrition Supplement for Cystic Fibrosis
NCT07163078 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A National Registry on Chinese Patients With Cystic Fibrosis
NCT05289245 ·Status: RECRUITING
-
The Use of Novel Diagnostic Tools to Increase Detection of Early Fibrosis in Cystic Fibrosis Related Liver Disease to Improve Clinical Management
NCT04277819 ·Status: COMPLETED
-
Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
NCT01772758 ·Status: COMPLETED ·Phase: PHASE2
-
Determinants of Early Cystic Fibrosis Lung Disease
NCT03579173 ·Status: COMPLETED
-
COVID-19 Antibody Responses In Cystic Fibrosis
NCT04863573 ·Status: UNKNOWN
-
Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis
NCT05239611 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF
NCT02109822 ·Status: COMPLETED
-
A Novel Assay to Quantify Treatment Response in Cystic Fibrosis (CF)
NCT01626157 ·Status: COMPLETED
-
Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents
NCT00758771 ·Status: COMPLETED
-
COVID-19 Antibody Responses in Cystic Fibrosis
NCT05052294 ·Status: ACTIVE_NOT_RECRUITING
-
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)
NCT02477319 ·Status: COMPLETED
-
Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening
NCT02270476 ·Status: RECRUITING
-
Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
NCT00381628 ·Status: COMPLETED
-
Idiopathic Pulmonary Fibrosis: a Case-control Study
NCT00005295 ·Status: TERMINATED